Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of AVT-01 5 mg once daily over 7 days in patients with moderate persistent atopic asthma
2006-004187-32Phase 2Completed
- Sponsor
- Avontec
- Start
- Feb 2008
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing AVT-01 5 mg once daily with Placebo (2 arms). Primary endpoint: Change in methacholine PC20 doubling concentration from day 0 to day 7. Started Feb 2008; status: completed.
02
Drugs
AVT-01
03
Conditions
asthma
Beyond the preview
Go deeper on 2006-004187-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004187-32.